Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
暂无分享,去创建一个
Marco Rovaris | Mario Zappia | Giancarlo Comi | Mauro Zaffaroni | Claudio Solaro | Roberto Bruno Bossio | Alfredo Granata | Simona Bonavita | Isabella Righini | Francesco Patti | Roberto Bergamaschi | Daniele Spitaleri | Silvia Messina | D. Centonze | M. Rovaris | G. Comi | M. Zaffaroni | R. Bergamaschi | C. Gasperini | R. B. Bossio | M. Mirabella | P. Cavalla | M. Zappia | F. Patti | E. Sessa | S. Bonavita | A. Francia | C. Solaro | V. Brescia Morra | D. Paolicelli | Massimiliano Mirabella | Diego Centonze | Vincenzo Brescia Morra | S. Messina | Gianfranco Costantino | Paola Cavalla | Salvatore Cottone | Maura Chiara Danni | Ada Francia | Alberto Gajofatto | Claudio Gasperini | Loredana Petrucci | Elisabetta Signoriello | Giorgia Teresa Maniscalco | Gabriella Spinicci | Manuela Matta | Graziella Pedà | Letizia Castelli | Edoardo Sessa | Damiano Paolicelli | D. Spitaleri | E. Signoriello | G. Maniscalco | S. Cottone | A. Gajofatto | L. Petrucci | L. Castelli | G. Costantino | M. Matta | Isabella Righini | M. Danni | G. Spinicci | A. Granata | G. Pedà
[1] J. Slof,et al. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy , 2015, Expert review of pharmacoeconomics & outcomes research.
[2] C. Collin,et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis , 2010, Neurological research.
[3] C. Vila,et al. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study , 2011, Expert review of pharmacoeconomics & outcomes research.
[4] N. Vasilyev,et al. New data on , 1970 .
[5] Carlo Pozzilli,et al. Overview of MS Spasticity , 2014, European Neurology.
[6] U. Zettl,et al. Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity , 2014, European Neurology.
[7] J. Wight,et al. Treatments for spasticity and pain in multiple sclerosis: a systematic review. , 2003, Health technology assessment.
[8] U. Zettl,et al. Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice , 2014, European Neurology.
[9] D. Wade,et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients , 2004, Multiple sclerosis.
[10] G. Izquierdo. Multiple sclerosis symptoms and spasticity management: new data. , 2017, Neurodegenerative disease management.
[11] A. Thompson,et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper , 2016, Multiple sclerosis.
[12] C. Young,et al. Anti-spasticity agents for multiple sclerosis. , 2003, The Cochrane database of systematic reviews.
[13] F. Patti,et al. Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey , 2014, Neuroepidemiology.
[14] S. Meuth,et al. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis , 2015, Expert review of neurotherapeutics.
[15] I. Lang,et al. Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis , 2012, PharmacoEconomics.
[16] J. Farrar,et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. , 2008, Clinical therapeutics.
[17] P. Vermersch. MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. , 2014, Neurodegenerative disease management.
[18] C. Collin,et al. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis , 2012, Journal of Neurology.
[19] D. Centonze,et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[20] J. Slof,et al. Sativex® in multiple sclerosis spasticity: a cost–effectiveness model , 2012, Expert review of pharmacoeconomics & outcomes research.
[21] P. Flachenecker. Evolution of multiple sclerosis spasticity-associated symptoms: latest data. , 2016, Neurodegenerative disease management.
[22] C. Pozzilli,et al. A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis , 2011, European journal of neurology.
[23] D. Wade,et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis , 2006, Multiple sclerosis.
[24] C. Collin,et al. Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis , 2007, European Journal of Neurology.
[25] Andrew Briggs,et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] C. Vila,et al. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. , 2014, Journal of comparative effectiveness research.
[27] C. Oreja-Guevara,et al. Observational Safety Study of THC:CBD Oromucosal Spray (Sativex) in Multiple Sclerosis Patients with Spasticity , 2015 .
[28] A. García-Merino,et al. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis , 2014, Expert review of neurotherapeutics.